Kairos Pharma Ltd (KAPA)
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company listed on the NYSE under the ticker KAPA. The company focuses on developing cancer therapeutics, with a pipeline that includes antibodies and small molecules aimed at prostate cancer, lung cancer, breast cancer, and glioblastoma. Its development programs include KROS 101, KROS 102, KROS 201, KROS 301, and KROS 401, each designed to target different immune and tumor-related pathways. Kairos Pharma is also developing ENV 105, an antibody therapeutic for prostate cancer patients resistant to androgen-targeted therapy, and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was incorporated in 2013, was formerly known as NanoGB13, Inc., and adopted the Kairos Pharma name in July 2016. It is based in Los Angeles, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-KAPA
|
$2.34
|
35.3% Upside
|
Undervalued
|
$49 2,732.5% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
December 2, 2026
|
1.4x
|
5.856 M
|
3.23 M
|
0.0%
|
66.4%
|
4.8
|
68.4%
|
